Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
45 hedge funds and large institutions have $26.6M invested in Viracta Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 6 closing their positions.
1,920% more call options, than puts
Call options by funds: $101K | Put options by funds: $5K
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 44 → 45 (+1)
27% less capital invested
Capital invested by funds: $36.6M → $26.6M (-$9.96M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.95M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.93M |
| 3 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$2.62M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.75M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$7.25M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.81M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
-$863K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$587K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$321K |
VIRX Hedge Fund Activity: Q2 2019 in Review
45 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2019, worth a combined $26.6M — down 27% from $36.6M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new VIRX positions and 6 closed out — a net gain of 1 holder — while 14 added to existing stakes and 8 trimmed.
The largest buyer was BVF Inc, adding an estimated $4.95M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $7.25M sold.
- 45 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2019, up from 44 in Q1 2019.
- Funds reported $26.6M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2019, down 27% quarter-over-quarter.
- 7 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2019 and 6 closed out, a net change of +1 holder.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2019 was BVF Inc, an estimated $4.95M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2019 was Eventide Asset Management, an estimated $7.25M sold.
Based on aggregated 13F filings for Q2 2019.